Axonics wins regulatory nod in Australia for latest sacral neuromod system

Axonics (Nasdaq:AXNX) announced today that it received regulatory approval in Australia for its R20 rechargeable sacral neuromodulation (SNM) system.

The implantable system provides therapy for patients suffering from overactive bladder or fecal incontinence. The R20 neurostimulator uses the same small 5cc form factor as the previous-generation R15. It pairs with the same tined lead and intuitive patient remote control. It also features enhanced programming capabilities with expanded MRI labeling.

R20 has a functional life in the body of at least 20 years and reduces charging frequency to every 6-10 months for just one hour.

Sign up for Blog Updates